The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics
Authors' conclusion
The combined BETAMI-DANBLOCK trial will have the potential to affect current clinical practice for beta-blocker therapy in patients with normal or mildly reduced LVEF after MI.
Study context
- Population
- Patients after myocardial infarction (MI) with normal or mildly reduced LVEF (≥40%), Denmark and Norwayrandomised as of July 2023
- Participants
- 5,228 patients
- Comparison
- Beta-blocker vs no beta-blocker after MI
- Primary endpoint
- Composite of:
- Adjudicated recurrent MI
- Incident HF
- Coronary revascularization
- Ischaemic stroke
- All-cause mortality
- Malignant ventricular arrhythmia
- Resuscitated cardiac arrest
Methodological detailsopen-label, event-driven, combined DANBLOCK and BETAMI trials, Primary safety endpoint: composite of recurrent MI, heart failure (HF), all-cause mortality, malignant ventricular arrhythmia or resuscitated cardiac arrest at 30 days
- Open-label
- Event-driven
- Combined DANBLOCK and BETAMI trials
- Primary safety endpoint: composite of recurrent MI, HF, all-cause mortality, malignant ventricular arrhythmia or resuscitated cardiac arrest at 30 days
Primary result
As reported in the abstract
Baseline characteristics (first 4000 randomised)
Median age
62 years
Men
79%
STEMI
48%
Normal LVEF
84%
Original publication
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics. Eur Heart J Cardiovasc Pharmacother. Published 28 November 2023. doi:10.
Summarised from the published abstract; every number is checked against it